Intravenous therapies for castration-resistant prostate cancer: Toxicities and adverse events

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4 SUPPL., 2012, Pages

  Singer, Eric A ^a   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cabazitaxel; Castration resistant prostate cancer (CRPC); Chemotherapy; Docetaxel; Mitoxantrone; Prostate cancer; Toxicity; Zoledronic acid

Indexed keywords

CABAZITAXEL; DOCETAXEL; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ANEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; HUMAN; HYPERSENSITIVITY REACTION; JAW OSTEONECROSIS; LEG EDEMA; MYALGIA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; STOMATITIS; TREATMENT DURATION;

ADMINISTRATION, INTRAVENOUS; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MITOXANTRONE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84863826255     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.09.003     Document Type: Review

References (24)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339:1036-1042.
4. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989, 321:419-424.
5. Singer E.A., Golijanin D.J., Messing E.M. Androgen deprivation therapy for advanced prostate cancer: Why does it fail and can its effects be prolonged?. Can J Urol 2008, 15:4381-4387.
6. Singer E.A., Golijanin D.J., Miyamoto H., et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008, 9:211-228.
7. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
8. Saad F., Hotte S.J. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J 2010, 4:380-384.
9. Mottet N., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59:572-583.
10. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
11. Flaig T.W., Tangen C.M., Hussain M.H., et al. Randomization reveals unexpected acute leukemia in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008, 26:1532-1536.
12. Martinez V., Mir O., Domont J., et al. Mitoxantrone-related acute myeloblastic leukemia in a patient with metastatic hormone-refractory prostate cancer. Anticancer Drugs 2007, 18:233-235.
13. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
14. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
15. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
16. Attard G., Greystoke A., Kaye S., et al. Update on tubulin-binding agents. Pathol Biol (Paris) 2006, 54:72-84.
17. Mita A.C., Denis L.J., Rowinsky E.K., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009, 15:723-730.
18. Pivot X., Koralewski P., Hidalgo J.L., et al. A multicenter phase II study of XRP6258 administered as a 1-HIV infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008, 19:1547-1552.
19. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet 2010, 376:1147-1154.
20. Wu Y., Rosenberg J.E., Taplin M.E. Novel agents and new therapeutics in castration-resistant prostate cancer. Curr Opin Oncol 2011, 23:290-296.
21. Yap T.A., Zivi A., Omlin A., et al. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011, 8:597-610.
22. Carlin B.I., Andriole G.L. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000, 88(12 Suppl):2989-2994.
23. Lee R.J., Saylor P.J., Smith M.R. Treatment and prevention of bone complications from prostate cancer. Bone 2011, 48:88-95.
24. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.